El Salvador vs Greece: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- El Salvador
- Greece
How they compare
Greece currently reports 553.75 deaths against 521.19 deaths in El Salvador, a difference of 32.56 deaths.
That makes Greece's figure about 1.1 times El Salvador's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Greece ahead.
El Salvador ranks 90th and Greece ranks 88th of 157 countries.
Across the 4 decades both report, El Salvador averaged higher in 3 and Greece in 1.
Head to head by decade
| Decade | El Salvador | Greece | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 64.77 deaths | 64.77 deaths | Greece |
| 2000s | 374.61 deaths | 267.56 deaths | 107.05 deaths | El Salvador |
| 2010s | 792.19 deaths | 455.55 deaths | 336.64 deaths | El Salvador |
| 2020s | 558.8 deaths | 550.71 deaths | 8.09 deaths | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, El Salvador or Greece?
- Greece, at 553.75 deaths against 521.19 deaths in El Salvador as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between El Salvador and Greece?
- 32.56 deaths, with Greece ahead.
- How many years of comparable data are there for El Salvador and Greece?
- 35 years are reported by both, from 1990 to 2024.
- How do El Salvador and Greece rank globally for hiv/aids deaths averted by antiretroviral therapy?
- El Salvador ranks 90th and Greece ranks 88th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.